Page last updated: 2024-10-28

1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetic Glomerulosclerosis

1-(5-isoquinolinesulfonyl)-2-methylpiperazine has been researched along with Diabetic Glomerulosclerosis in 14 studies

1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine: A specific protein kinase C inhibitor, which inhibits superoxide release from human neutrophils (PMN) stimulated with phorbol myristate acetate or synthetic diacylglycerol.
1-(5-isoquinolinesulfonyl)-2-methylpiperazine : A member of the class of N-sulfonylpiperazines that is 2-methylpiperazine substituted at position 1 by a 5-isoquinolinesulfonyl group.

Research Excerpts

ExcerptRelevanceReference
"Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs."1.42Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015)
"The fasudil-treated mice exhibited a significant reduction in ROCK activity, albuminuria, glomerular collagen IV accumulation, and urinary collagen IV excretion compared with untreated db/db mice."1.35Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. ( Danesh, FR; Kolavennu, V; Peng, H; Wang, Y; Zeng, L, 2008)
"The treatment with fasudil after the development of diabetes improved the metabolic abnormalities in OLETF rats, but could not suppress the progression of nephropathy."1.34A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. ( Higashi, K; Hyodo, N; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Oda, T; Suzuki, S; Yamada, M; Yamamoto, K, 2007)
"Tubulointerstitial fibrosis in diabetic nephropathy (DN) was investigated using an in vitro tissue model of remodeling, to determine the pathogenic mechanism of fibrosis that leads to renal atrophy, i."1.34Contraction of tubulointerstitial fibrosis tissue in diabetic nephropathy, as demonstrated in an in vitro fibrosis model. ( Abe, H; Fujikura, Y; Ina, K; Kitamura, H; Miyazaki, T; Tatsukawa, S, 2007)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (35.71)29.6817
2010's7 (50.00)24.3611
2020's2 (14.29)2.80

Authors

AuthorsStudies
Nagai, Y1
Matoba, K2
Yako, H1
Ohashi, S1
Sekiguchi, K1
Mitsuyoshi, E1
Sango, K1
Kawanami, D2
Utsunomiya, K3
Nishimura, R1
Xie, F1
Lei, J1
Ran, M1
Li, Y3
Deng, L1
Feng, J1
Zhong, Y1
Li, J1
Mishra, RK1
Alokam, R1
Sriram, D1
Yogeeswari, P1
Okada, R1
Tsukamoto, M1
Kinoshita, J1
Ito, T1
Ishizawa, S2
Kanazawa, Y2
Yokota, T2
Murai, N1
Matsufuji, S1
Takahashi-Fujigasaki, J1
Li, T1
Yang, GM1
Zhu, Y1
Wu, Y1
Chen, XY1
Lan, D1
Tian, KL1
Liu, LM1
Peng, H3
Wang, C2
Zhang, J1
Chen, Y1
Chen, W1
Cao, J1
Wang, Y2
Hu, Z1
Lou, T2
Rao, J1
Ye, Z1
Tang, H1
Lai, W1
Huang, W1
Komers, R2
Oyama, TT1
Beard, DR1
Tikellis, C1
Xu, B1
Lotspeich, DF1
Anderson, S1
Kikuchi, Y1
Yamada, M1
Imakiire, T1
Kushiyama, T1
Higashi, K1
Hyodo, N1
Yamamoto, K1
Oda, T1
Suzuki, S1
Miura, S1
Gojo, A1
Taniguchi, K1
Kurata, H1
Tajima, N1
Ina, K1
Kitamura, H1
Tatsukawa, S1
Miyazaki, T1
Abe, H1
Fujikura, Y1
Kolavennu, V1
Zeng, L1
Danesh, FR1
Bach, LA1

Reviews

2 reviews available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetic Glomerulosclerosis

ArticleYear
Potential role of Rho kinase inhibitors in combating diabetes-related complications including diabetic neuropathy--a review.
    Current diabetes reviews, 2013, Volume: 9, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cardiomyopathies; Diabetes Complicat

2013
Rho kinase inhibition in diabetic nephropathy.
    Current opinion in nephrology and hypertension, 2011, Volume: 20, Issue:1

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetic Nephropathies; Humans; Kidney; Prot

2011

Other Studies

12 other studies available for 1-(5-isoquinolinesulfonyl)-2-methylpiperazine and Diabetic Glomerulosclerosis

ArticleYear
Rho-kinase inhibitor restores glomerular fatty acid metabolism in diabetic kidney disease.
    Biochemical and biophysical research communications, 2023, 03-15, Volume: 649

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Diabetes Mellitus; Diabetic Nephropathies; K

2023
Attenuation of Diabetic Nephropathy in Diabetic Mice by Fasudil through Regulation of Macrophage Polarization.
    Journal of diabetes research, 2020, Volume: 2020

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Cell Polarity; Diabetes Melli

2020
Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α.
    Kidney international, 2013, Volume: 84, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Albuminuria; Animals; Diabetes Mellitus, Type 2; Diab

2013
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
    American journal of physiology. Endocrinology and metabolism, 2015, Feb-15, Volume: 308, Issue:4

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu

2015
ROCK1 Induces Endothelial-to-Mesenchymal Transition in Glomeruli to Aggravate Albuminuria in Diabetic Nephropathy.
    Scientific reports, 2016, Feb-04, Volume: 6

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actins; Albuminuria; Animals; Antigens, CD; Cadherins

2016
The RhoA/ROCK Pathway Ameliorates Adhesion and Inflammatory Infiltration Induced by AGEs in Glomerular Endothelial Cells.
    Scientific reports, 2017, 01-05, Volume: 7

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cell Adhesion; Cell Movement; Cells,

2017
Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure.
    Kidney international, 2011, Volume: 79, Issue:4

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II Type 1 Receptor Blockers; Animals; Blo

2011
A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.
    The Journal of endocrinology, 2007, Volume: 192, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Carrier Proteins; Diabetes Me

2007
The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.
    European journal of pharmacology, 2007, Jul-30, Volume: 568, Issue:1-3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Bl

2007
Contraction of tubulointerstitial fibrosis tissue in diabetic nephropathy, as demonstrated in an in vitro fibrosis model.
    Virchows Archiv : an international journal of pathology, 2007, Volume: 451, Issue:5

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Cells, Cultured; Collagen; Cytochala

2007
Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control.
    Diabetes, 2008, Volume: 57, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood Glucose; Collagen Type IV; Diabetic Ne

2008
Rho kinase inhibition: a new approach for treating diabetic nephropathy?
    Diabetes, 2008, Volume: 57, Issue:3

    Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Diabetic Nephropathies; Humans; Mice

2008